Healthcare Decliners: SunLink Health Systems, Inc. (NYSEMKT:SSY), Recro Pharma Inc (NASDAQ:REPH), OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), Retrophin Inc (NASDAQ:RTRX)

SunLink Health Systems Inc. (NYSEMKT:SSY) said that net loss for the third-quarter ended March 31, 2014 widened to $964,000 or $0.10 per share, from $186,000 or $0.02 per share last year. Loss from continuing operations for the quarter was $911,000 or $0.10 per share, compared to a loss from continuing operations of $197,000 or $0.02 per share in the prior year. Quarterly operating loss from continuing operations for the quarter was $998,000, compared to an operating loss from continuing operations of $268,000 in the prior year. The operating loss increased in the current year’s quarter primarily due to decreased patient volume in SunLink’s Healthcare Facilities Segment. SunLink Health Systems, Inc. (NYSEMKT:SSY) stock performance was -5.74% in last session and finished the day at $1.15. Traded volume was 12,136.00million shares in the last session and the average volume of the stock remained million shares. The beta of the stock remained 1.31. SunLink Health Systems, Inc. (NYSEMKT:SSY) insider ownership is 64.88%.

Recro Pharma Inc (NASDAQ:REPH) in it quarterly report on 136 May 2014 revealed that as of March 31, 2014 and December 31, 2013, they had $29,905,000 and $13,000, respectively, in cash and cash equivalents. The net proceeds from the IPO, together with interest, will be sufficient to fund our current operations through the end of 2015. Since inception through March 31, 2014, financed product development, operations and capital expenditures primarily from private sales of $4.0 million of our Series A Stock, $9.6 million of our Bridge Notes and $30.3 million from the IPO. Recro Pharma Inc (NASDAQ:REPH) dropped -6.08 percent to $6.02 Thursday on volume of 18.60K shares. The intra-day range of the stock was $6.02 to $6.78. Recro Pharma Inc (NASDAQ:REPH) has a market capitalization of $46.40million.

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average for OGXI broke out below the 200 Day Simple Moving Average, suggesting short-term bearishness. OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)’s stock on May 29, 2014 reported a decrease of -5.34% to the closing price of $3.90. Its fifty two weeks range is $3.55 -$14.25. The total market capitalization recorded $57.54million. The overall volume in the last trading session was 305.20K shares. In its share capital, OGXI has 14.76million outstanding shares.

Retrophin Inc. (NASDAQ:RTRX) said it has entered into a license agreement with Mission Pharmacal Co. for U.S. marketing rights to recurring-kidney-stone treatment Thiola, while boosting its revenue outlook. Shares of the developer of treatments for rare diseases jumped 21% to $15.59 in after-hours trading. On Thursday, shares of Retrophin Inc (NASDAQ:RTRX) dropped -7.54% to close the day at $12.88. Company monthly performance is recorded as -2.72%. Retrophin Inc (NASDAQ:RTRX) quarterly revenue growth is -32.67%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone